source
- Boulevard Bio raises $65M to expand immunology pipeline, eyes Vera's IgAN candidateBoulevard Bio announced it has secured $65 million in financing to broaden its immunology portfolio. The new capital will support the development of two immune‑resetting drugs the company discovere…
- Boulevard Bio launches with $65 million to develop bispecific antibodies for IgA nephropathy and other autoimmune diseasesBoulevard Bio, a new biotech co-founded by autoimmune researcher Georg Schett and former Sanofi CSO Frank Nestle, announced its launch on Wednesday with $65 million in funding. The company’s first…